Top Summary
This section of the US bill amends the Controlled Substances Act to modify the conditions under which a pharmacy can deliver a controlled substance to a prescribing practitioner, specifically limiting this delivery to drugs in schedules III, IV, or V that are administered by injection or implantation for maintenance or detoxification treatment, or that are subject to a risk evaluation and mitigation strategy requiring post-administration monitoring by a healthcare provider.
Original Bill Text:
SEC. 401.Delivery of a controlled substance by a pharmacy to a prescribing practitioner.
Section 309A(a) of the Controlled Substances Act (21 U.S.C. 829a(a)) is amended by striking paragraph (2) and inserting the following:
“(2) the controlled substance is a drug in schedule III, IV, or V to be administered—
“(A) by injection or implantation for the purpose of maintenance or detoxification treatment; or
“(B) subject to a risk evaluation and mitigation strategy pursuant to section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) that includes elements to assure safe use of the drug described in subsection (f)(3)(E) of such section, including a requirement for post-administration monitoring by a health care provider;”.